#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
Click to read this study in The Lancet Oncology.
Click to read this study in The Lancet Oncology.
1. OS in triplet combination therapy (atezolizumab, vemurafenib, and cobimetinib) while numerally better, was not statistically improved when compared to ...
1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2. ...
Click to read the study in Clinical Cancer Research.
Click to read the study in the European Journal of Cancer.
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
Click to read the study in The Lancet Oncology.
Click to read the study in the European Journal of Cancer.
Click to read the study in the European Journal of Cancer.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.